报价延迟最少15分钟:2026/03/05 19:48 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.9501 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.38/0.04
|
|
企业价值
9.76B
|
| 资产负债 |
|
每股账面净值
-0.49
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
113.29M
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States. |
